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The  zebraﬁsh  (Danio  rerio)  is  a very  popular  vertebrate  model  system,  especially  embryos  represent  a
valuable  tool  for  in  vivo pharmacological  assays.  This  is mainly  due  to the  zebraﬁsh  advantages  when
compared  to other  animal  models.
Erythropoietin  is  a glycoprotein  hormone  that  acts principally  on  erythroid  progenitors,  stimulating
their  survival,  proliferation  and  differentiation.  Recombinant  human  erythropoietin  (rhEPO)  has  been
widely  used  in medicine  to treat  anemia  and  it is one  of  the  best-selling  biotherapeutics  worldwide.
The recombinant  molecule,  industrially  produced  in  CHO  cells,  has  the same amino  acid  sequence  of
endogenous  human  erythropoietin,  but  differs  in the glycosylation  pattern.  This may  inﬂuence  efﬁcacy
and  safety,  particularly  immunogenicity,  of  the  ﬁnal  product.
We employed  the  zebraﬁsh  embryo  as a vertebrate  animal  model  to perform  in  vivo  pharmacological
assays.  We  conducted  a functional  analysis  of  rhEPO  alpha  Eprex® and  two biosimilars,  the  erythropoietin
alpha  Binocrit® and  zeta  Retacrit®.
By  in  silico  analysis  and  3D  modeling  we proved  the  interaction  between  recombinant  human  erythro-
poietin  and  zebraﬁsh  endogenous  erythropoietin  receptor.  Then  we  treated  zebraﬁsh  embryos  with  the  3
rhEPOs and  we investigated  their effect  on erythrocytes  production  with  different  assays.  By  real  time-PCR
we observed  the relative  upregulation  of  gata1  (2.4  ± 0.3  fold),  embryonic  -Hb  (1.9 ± 0.2  fold)  and  -Hb
(1.6  ±  0.1  fold)  transcripts.  A signiﬁcant  increase  in  Stat5  phosphorylation  was  also  assessed  in  embryos
treated  with  rhEPOs  when  compared  with  the  negative  controls.  Live  imaging  in  tg (kdrl:EGFP;  gata1:ds-
red)  embryos,  o-dianisidine  positive  area  quantiﬁcation  and  cyanomethemoglobin  content  quantiﬁcation
revealed  a  1.8  ±  0.3  fold  increase  of erythrocytes  amount  in embryos  treated  with  rhEPOs  when  compared
with  the  negative  controls.  Finally,  we veriﬁed  that  recombinant  human  erythropoietins  did  not  cause
any  inﬂammatory  response  in  the treated  embryos.
Our  data  showed  that  zebraﬁsh  embryo  can  be  a valuable  tool  to study  in vivo  effects  of complex
pharmacological  compounds,  such  as recombinant  human  glycoproteins,  allowing  to  perform  fast  and
reproducible  pharmacological  assays  with  excellent  results.© 2015  The  Authors.  Publis
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. Introduction
The zebraﬁsh (Danio rerio) is widely used as an experimental
ertebrate animal model in many ﬁelds of scientiﬁc research. For
nstance, because of eggs transparency, rapid ex utero development
nd easy access to experimental manipulation, zebraﬁsh embryos
epresent a valuable tool for in vivo pharmacological assays,
ffering several advantages when compared to other animal mod-
ls. Strong correlations have been observed between the effects
f many compounds tested both on zebraﬁsh and humans. More-
ver, drug administration to embryos is simple and fast, and a large
umber of individuals can be analyzed at the same time [1–3].
The zebraﬁsh is also a very useful animal model to study in vivo
ertebrate hematopoiesis [4]. The genes and the molecular path-
ays involved in hematopoiesis are very well conserved between
ebraﬁsh and higher vertebrates. Moreover, morphology and func-
ion of zebraﬁsh blood cells are comparable to their mammalian
ounterparts [5,6].
The ﬁrst myeloid progenitors mature into primitive
acrophages and granulocytes, which have the ability to migrate
owards the site of a wound and to phagocytose foreign particles
y 2 days post fertilization (dpf). Proerythroblasts are the ﬁrst
lood cell entering the circulation around 24 hpf and mature into
rimitive erythrocytes, that are the only circulating red blood cells
ill 4 dpf [5,7].
Zebraﬁsh erythrocytes show the typical elliptical shape and, as
ll the other nonmammalian vertebrates, they retain their nucleus
lso in the mature adult stage. Erythropoiesis is ﬁnely regulated by
ifferent molecular mechanisms, such as transcription factors (i.e.,
cl,  lmo  and gata family) or activation of signaling pathways, the
ost important of which is the erythropoietin pathway [8].
Erythropoietin (EPO) is a glycoprotein hormone that acts
rincipally on erythroid progenitors, stimulating their survival,
roliferation and differentiation. In mammals, EPO is produced
y fetal hepatocytes during development and mainly by per-
tubular interstitial ﬁbroblasts in adult kidney. EPO binding to its
omodimeric receptor (EPOR) on progenitors surface, causes a con-
ormational change in EPOR intracellular domain. This leads to
AK2 transphosphorylation and EPOR activation, which activates
he downstream signaling cascade via STAT5, PI3K/AKT and MAPK
athways [9].
Human erythropoietin gene (hEPO) was cloned and character-
zed for the ﬁrst time in 1985 [10,11]. Since then, recombinant
NA technology allowed the production of recombinant human
rythropoietin (rhEPO) using mammalian Chinese hamster ovary
CHO) cells as expression system. rhEPO has been widely used to
reat patients with chronic anemia caused by renal failure, but also
hemotherapy-associated anemia in cancer patients, severe ane-
ia  due to antiviral therapy in AIDS patients and perioperative
nemia after surgery [12].
In 2007, two decades after human erythropoietin synthesis,
ebraﬁsh erythropoietin and erythropoietin receptor genes (zepo
nd zepor, respectively) were cloned and biochemically character-
zed [13,14]. It has been shown that, despite the low identity score
etween human and zebraﬁsh erythropoietin proteins (hEPO and
Epo, respectively), the most important residues are maintained
mong them. As well, protein sequences of human and zebraﬁsh
rythropoietin receptors (hEPOR and zEpor, respectively) share low
dentity score, but very well conserved functional domains [15]. The
iological function of both zEpo and zEpor seems to be maintained:
ownregulation of zepo or zepor genes causes a dramatic decrease
f hemoglobin, while overexpression of zepo leads to an increase in
irculating erythroid cells [15].
Due to these ﬁndings, we employed the zebraﬁsh embryo as
 vertebrate animal model to study the effects of 3 commercially
vailable rhEPOs in vivo. In the present paper we performed a func-l Research 102 (2015) 12–21 13
tional analysis of Eprex® and its biosimilars Binocrit® and Retacrit®
[16]. Eprex® was the ﬁrst patented rhEPO approved by FDA in 1989,
while the erythropoietin alpha Binocrit® and zeta Retacrit® were
authorized as Eprex® biosimilars in 2007. Because of the similar
amino acid sequence and the glycosylation pattern, the erythropoi-
etin zeta Retacrit® is considered homologous of the erythropoietins
alpha [17]. Bioequivalence of erythropoietin alpha and zeta was
demonstrated by pharmacokinetic studies [18]. The biosimilarity
between the 3 different rhEPO proteins was  also demonstrated in
our laboratory by a proteomic approach (submitted manuscript).
In the present study we ﬁrst performed a computational analysis
to predict if rhEPO could interact with zEpor. We treated zebraﬁsh
embryos with the 3 rhEPOs and we  investigated their effect on
erythrocytes production, analyzing changes both in quality and in
quantity. Moreover, we  examined whether the presence of these
exogenous compounds could cause an inﬂammatory response in
the treated embryos. In this paper, we ﬁrstly show that zebraﬁsh
embryo can be a good animal model to study in vivo effects of
complex pharmacological compounds.
2. Material and methods
2.1. In silico analysis
The amino acid sequence of rhEPO published on the European
Pharmacopoeia 8th edition (http://online6.edqm.eu/ep805/) was
used to BLAST search the human and zebraﬁsh Ensembl genome
sequence database at http://www.ensembl.org The database sup-
plies the more updated genome assembly, which is GRCh38 (Db
version 78.38) for human, and Zv9 (Db version 78.9) for zebraﬁsh
[19]. The “tblastn” and the “blastp” algorithms allowed us to iden-
tify the human endogenous erythropoietin transcript and protein
sequences, respectively. Three zebraﬁsh splice variants of the same
erythropoietin gene were found, and each of these transcripts
encoded for a protein. The hEPO protein information collected in
the UniProt database (http://www.uniprot.org) were used to obtain
hEPOR entry, in the “Protein Interaction” section [20]. Ensembl full
length sequences of human erythropoietin receptor transcript and
protein were deduced and used to BLAST search the zebraﬁsh Zv9
Ensembl genome assembly. One full length zebraﬁsh transcript,
encoding for one erythropoietin receptor protein, was identiﬁed.
A comparative analysis of gene organization between human
and zebraﬁsh erythropoietin and EPO receptor genes was carried
out, employing information supplied by the Ensembl database [19].
Synteny analysis was  performed using the Synteny database
(http://syntenydb.uoregon.edu/synteny db/) and the Genomi-
cus genome browser (http://www.genomicus.biologie.ens.fr/
genomicus-78.01/cgi-bin/search.pl) [21,22].
The protein sequences of rhEPO, endogenous hEPO and zEpo
were employed to perform multiple sequence alignment by
ClustalW program (http://www.ebi.ac.uk/Tools/msa/clustalw2/)
[23]. The same analysis was  carried out using hEPOR and zEpor
protein sequences.
2.2. Homology modeling
To better evaluate the functional similarity between human
and zebraﬁsh erythropoietin receptors and to assess if rhEPO
could recognize and bind the zebraﬁsh erythropoietin receptor,
a 3D model of zEpor was created. The zEpor protein sequence
(NP 001036799.1) and PSI-BLAST were used to identify a list of 7
suitable templates from the RCSB protein data bank (http://www.
rcsb.org/pdb/home/home.do) [24].
The 1EER complex, representing the extracellular portion of
hEPOR, was selected as best template given its similarity with zEpor
1 logica
a
B
m
a
i
t
ﬁ
h
h
i
s
d
p
Y
p
t
r
a
t
a
o
m
2
t
a
w
g
m
i
M
c
F
v
w
(
2
t
s
C
(
t
t
a
T
d
i
i
a
i
J
c
2
i4 M. Guarienti et al. / Pharmaco
nd the inclusion of the human EPO substrate. A single chain (chain
) from this template was used in I-Tasser (http://zhanglab.ccmb.
ed.umich.edu/I-TASSER/) [25] to perform homology modeling
nd generate the predicted structure of zEpor extracellular domain,
dentiﬁed from residues Y26 to T232. The N-terminal domain and
he transmembrane and intracellular regions were excluded. The
nal model of zEpor monomer was then superimposed on the
uman protein structure to generate a prediction of the zEpor
omo-dimer and to evaluate the placement of relevant residues
nvolved in disulﬁde bonds and contact surface with hEPO. Protein
tructure was visualized and reﬁned using PyMOL v1.7.0.
To better analyze the possible interaction between zEpor homo-
imer and hEPO, a complex between the two molecules was
redicted using GRAMM-X [26], with the 3 residues F108, I164 and
207, imposed as obligate contact amino acids in zEpor. The best
redicted complex that resemble the correct hEPO orientation was
hen used to evaluate contact surfaces and placement of relevant
esidues in zEpor model.
The surface interaction between zEpor and hEPO was evalu-
ted using SC program from CCP4 package [27,28], considering
he predicted complex of hEPO ligand and zEpor structure, and
n interaction space of 5 Å. The same calculation was performed
n the 1EER structure considering chain B of the hEPOR and hEPO
olecules.
.3. Fish maintenance and egg collection
All embryos were handled according to national and interna-
ional animal care guidelines. Current Italian rules do not require
pproval for research on zebraﬁsh embryos.
Adult zebraﬁsh of two strains were used for egg production: the
ild type AB strain and the transgenic line casper tg (kdrl:EGFP;
ata1:ds-red), the last one a kind gift of Prof. Cotelli (Depart-
ent of Biosciences, University of Milan). Fishes were maintained
n the zebraﬁsh facility at University of Brescia (Department of
olecular and Translational Medicine) under standard laboratory
onditions as described, at 28 ◦C on a 14 h light/10 h dark cycle [29].
ertilized eggs were collected immediately after spawning, har-
ested, washed and placed in ﬁsh water. The developing embryos
ere raised in a 28 ◦C incubator in 0.003% 1-phenyl-2-thiourea
Sigma–Aldrich) to prevent pigmentation.
.4. rhEPO administration
Three commercially available rhEPOs, sold as injectable solu-
ions in preﬁlled syringes (1 ml  at 40,000 IU/ml), were used as stock
olutions. The following batch were employed: Eprex® (Janssen-
ilag©) #DGS5G00, Binocrit® (Sandoz©) #47021202 and Retacrit®
Hospira©) #3E366G3.
Eprex®, Binocrit® and Retacrit® stock solutions were diluted
o the ﬁnal concentration of 48 IU/ml in 0.05% phenol red solu-
ion (Sigma–Aldrich). The 0.05% phenol red solution without
ny pharmaceutical compound was used as negative control.
he compounds were administered in two different ways to the
echorionated embryos. For the subsequent erythrocytes visual-
zation and quantiﬁcation experiments, 4 nl of each compound was
njected into the common cardinal vein of 48 hpf embryos [30]. To
ssess primitive myelocytes activation, 1 nl of each dilution was
njected into the otic cavity of 72 hpf embryos. Escherichia coli
M109 bacteria in 0.05% phenol red solution were used as positive
ontrol [31]..5. Real time quantitative RT-PCR (Q-RT-PCR)
Total RNA was extracted from groups of 30 embryos for each
njected compound using the RNAeasy kit (Qiagen) and 1 mg  wasl Research 102 (2015) 12–21
transcribed into cDNA, using the M-MLV  reverse transcriptase
(Promega). Relative gene expression of gata1, -eHb and -eHb [32]
was evaluated by Q-RT-PCR with the ViiA7 Real Time PCR System
(Life Technologies), using the SYBR Green Method (Bio-Rad). Analy-
sis was performed in triplicate, Ct was calculated using -actin as
the housekeeping gene. The experiment was  repeated twice, using
different groups of embryos.
2.6. Western blot
Total embryo protein extracts were obtained by homogeniz-
ing groups of 10 treated embryos in lysis buffer (10 mM Tris pH
7.4, 150 mM NaCl, 5 mM EDTA, 10% Triton X-100 with a cocktail
of protease and phosphatase inhibitors). For Western blot anal-
ysis 25 g of protein extracts were loaded per lane on a 10%
Mini-PROTEAN TGX Gel (Bio-Rad) and transferred to a nitrocel-
lulose paper. The membrane was  incubated with 1:200 rabbit
anti-Phospho-Stat5 primary antibody (Cell Signaling) overnight at
4 ◦C, followed by 1:1500 IRDye 800RD or 680RD secondary antibody
(LI-COR Biotechnology) for 1 h at RT. Membranes were washed
and reprobed with anti-Actin primary antibody (Sigma–Aldrich).
The Odyssey Infrared Imaging System (LI-COR Biotechnology) was
employed for protein detection. The Western blot analysis was
repeated 3 times.
2.7. Erythrocytes visualization and quantiﬁcation
Treated embryos were incubated at 28 ◦C for 4 h after injection
and then used for erythrocytes visualization and/or quantiﬁcation.
Each experiment was  repeated 3 times.
Groups of 25 transgenic casper treated embryos were anes-
thetized in tricaine (Sigma–Aldrich) and photographed under a
Leica MZ16F stereomicroscope equipped with GFP3 and G ﬂuores-
cence ﬁlters, DFC 480 digital camera and LAS Leica Imaging software
(Leica, Wetzlar, Germany). Red and green signals were quantiﬁed
by using ImageJ 1.45 s image analysis software.
Groups of 25 wild type embryos for each injected com-
pound were ﬁxed in 4% paraformaldehyde overnight at 4 ◦C.
O-Dianisidine staining was performed as described in literature
to detect hemoglobin in red blood cells [13]. To visualize ery-
throcytes distribution, embryos were mounted in agarose-coated
dishes and photographed. Images were used to quantify erythro-
cytes on selected region of interest by using ImageJ 1.45 s image
analysis software.
Hemoglobin quantiﬁcation on total embryo extract was per-
formed by using a modiﬁed cyanomethemoglobin method [33].
Groups of 20 wild type embryos for each injected compound
were anesthetized in tricaine (Sigma–Aldrich) and sonicated in
1 ml  of Drabkin solution (Sigma–Aldrich). After centrifugation,
absorbance of the supernatant of each sample was measured
at 540 nm and it was  linearly correlated with hemoglobin con-
tent.
2.8. Macrophages and granulocytes quantiﬁcation
Groups of 40 treated embryos for each compound were incu-
bated at 28 ◦C for 2 h after injection and then ﬁxed in 4%
paraformaldehyde in PBS overnight at 4 ◦C. Whole-mount in situ
hybridization (WISH) was  performed according to Thisse protocol
[34]. pu1, lplastin and mpx were used as probes to detect leukocyte
precursors, macrophages and neutrophils [7,35]. Embryos were
mounted in agarose-coated dishes and images were taken with
a Leica MZ16F stereomicroscope equipped with DFC 480 digital
camera and LAS Leica Imaging software (Leica, Wetzlar, Germany).
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eucocytes quantiﬁcation was performed using ImageJ 1.45 s image
nalysis software. The experiment was repeated 3 times.
.9. Statistical analysis
Quantiﬁcations are expressed as mean ± standard deviation of
ndependent experiments. Statistical analysis were made using
raphPad Prism 6.01 version (GraphPad Software). Analysis of vari-
nce (one-way ANOVA) followed by Dunnett’s test was  performed
o evaluate signiﬁcant differences between the groups of data (p
alue < 0.05).
. Results and discussion
In order to evaluate if zebraﬁsh could be used as an animal
odel for rhEPO functional analysis, we ﬁrst assessed the simi-
arity between human and zebraﬁsh erythropoietin receptors by
omputational analysis and 3D modeling techniques. Then we
nvestigated the rhEPOs effects on erythrocytes production and
heir inﬂammatory response.
.1. In silico analysis and homology modeling
In order to identify the hEPO gene ortholog in zebraﬁsh, the 165
mino acids sequence of rhEPO was used as query in a BLAST search
erformed against the human and zebraﬁsh Ensembl genome
equence database at http://www.ensembl.org [19]. The rhEPO
equence fully matched with the amino acids 28-192 of the human
ndogenous immature erythropoietin protein ENSP00000252723,
orresponding to the RefSeq: NP 000790.2 on the Reference
equence peptide database at NCBI (http://www.ncbi.nlm.nih.gov,
efSeq Release 69) [36]. The hEPO protein is encoded by the 1330 bp
ranscript ENST00000252723 (RefSeq: NM 000799.2), which is the
roduct of the hEPO gene ENSG00000130427 located on human
hromosome 7.
In zebraﬁsh, according to literature, we found 3 splice vari-
nts of the same zepo gene (ENSDARG00000055163), located
n zebraﬁsh chromosome 7 [15]. The 3 zepo transcripts on
he Ensembl database are called respectively epo-001 (ENS-
ART00000111066), epo-002 (ENSDART00000020288) and epo-
01 (ENSDART00000077483). They correspond to the NCBI zepo
soforms L2 (RefSeq: NM 001038009), L1 (RefSeq: NM 001115128)
nd S (RefSeq: NM 001115127), respectively.
Both human and zebraﬁsh genes have a very similar organiza-
ion, consisting of 5 coding exons and 4 introns. The shortest zepo
soform 201 (or S isoform), with only four coding exons, differs from
he other ones.
It is well established that a conserved co-localization of gene
lusters among different species often correspond to a conserved
rotein function [37]. A synteny analysis was performed between
he human and zebraﬁsh chromosome 7, in the genomic regions
hat contain the erythropoietin gene (Fig. S1A and B). By using the
enomicus genome browser (http://www.genomicus.biologie.ens.
r/genomicus-78.01/cgi-bin/search.pl) [22] we found 5 ortholog
enes in the erythropoietin syntenic region, two  of which main-
ained the same orientation and 3 orientated in the opposite
irection (Fig. S1A). The analysis was repeated by using the Synteny
atabase (http://syntenydb.uoregon.edu/synteny db/) [21], which
llowed to evaluate a more extended genomic region. By analyzing
 100-gene window, 3 more ortholog genes associated with the ery-
hropoietin gene were highlighted, and they maintained the same
rientation on both chromosomes (Fig. S1B).
The amino acid sequences of hEPO and zEpo were employed
o perform ClustalW multiple sequence alignment [23]. The 3
ebraﬁsh splice variants of the zepo gene encode for 3 proteins,l Research 102 (2015) 12–21 15
that are named respectively Epo-L1 (RefSeq: NP 001108600), Epo-
L2 (RefSeq: NP 001033098) and Epo-S (RefSeq: NP 001108599).
The 3 isoforms are identical, except for only few amino acids in
the N-terminal signal peptide (Fig. S1C), that is cleaved in the 3
mature forms. The L1 isoform was used to perform protein align-
ment, because it is the longest isoform and the most abundant [15].
The hEPO amino acid sequence covered 99% of zEpo sequence, with
34.55% identity and 66% similarity (Fig. S1D). By using the infor-
mation collected in the UniProt database (http://www.uniprot.org)
[20] we  identiﬁed in the human hEPO sequence (UniProt: P01588)
the most important amino acids, responsible for erythropoietin
post-translational modiﬁcations (Fig. S1D). The 4 cysteine Cys34,
Cys56, Cys60 and Cys188 were conserved in the zEpo sequence
(in position 33, 55, 59 and 181, respectively). These amino acids
are essential to form two  disulﬁde bond, necessary for the correct
protein folding and function. Moreover, the O-glycosylation site in
position 153 and 2 out of 3 N-glycosylation sites in position 65 and
110 were conserved in the zebraﬁsh zEpo sequence (in position
144, 64 and 104, respectively). The glycosylation of erythropoi-
etin is important for its correct function and half life [38,39] and
these conserved residues suggest functional conservation between
human and zebraﬁsh erythropoietin.
The information supplied by the UniProt database (http://www.
uniprot.org) [20] allowed us to identify, in the “Protein Interac-
tion” section, the human full length hEPOR entry, UniProt: P19235.
This was  used to search the Ensembl database for hEPOR 508
amino acids full length protein sequence (ENSP00000222139)
[19]. The hEPOR protein is encoded by the 2411 bp tran-
script ENST00000222139, which is the product of the hEPOR
gene ENSG00000187266 located on human chromosome 19. The
Ensembl human erythropoietin receptor protein and transcript
sequences correspond to the NCBI database RefSeq: NP 000112 and
RefSeq: NM 000121, respectively [36].
The hEPOR sequence was  used to BLAST search the zebraﬁsh
Zv9 Ensembl genome assembly [19]. We  identiﬁed one full
length zebraﬁsh transcript ENSDART00000064033 (RefSeq:
NM 001043334) which is the product of zepor gene ENS-
DARG00000043609, located on zebraﬁsh chromosome 3. The
1656 bp zebraﬁsh transcript encoded for the 509aa zEpor protein
ENSDARP00000064032 (RefSeq: NP 001036799).
The gene organization of both human and zebraﬁsh erythropoi-
etin receptor is very similar, constituted by eight coding exons and
seven introns. The genomic regions that contain the erythropoietin
receptor gene on human chromosome 19 and zebraﬁsh chromo-
some 3 showed a high degree of synteny (Fig. S2A and B). The
Genomicus genome browser underlined ten ortholog genes in the
syntenic region (Fig. S2A), while by using a 100-gene window in
the Synteny database we found nine more ortholog genes asso-
ciated with the erythropoietin receptor gene on both human and
zebraﬁsh chromosomes (Fig. S2B) [21,22].
A ClustalW multiple sequence alignment was performed by
using the amino acid sequences of hEPOR and zEpor as inputs
(Fig. S2C) [23]. The human protein covered 97% of the whole
zebraﬁsh sequence, with an identity score of 27.11% and an over-
all similarity of 62%. The most important residues and motifs of
the human hEPOR sequence, annotated in the UniProt database,
were conserved also in the zebraﬁsh zEpor sequence (Fig. S2C)
[20]. In the extracellular region the four cysteine Cys52, Cys62,
Cys91 and Cys107, necessary to form two  disulﬁde bond, were
conserved (respectively Cys44, Cys54, Cys83 and Cys100 in zEpor).
The WSXWS  motif, essential for the correct folding and function
of the erythropoietin receptor, was  present in both proteins (aa
233-237 in hEPOR, aa 221-225 in zEpor). Moreover, the 3 residues
responsible for the ligand binding, Phe117, Met174 and Phe229
in hEPOR, were also conserved in the zEpor sequence (Phe108,
Ile164 and Tyr217). The transmembrane domain had two  con-
16 M. Guarienti et al. / Pharmacological Research 102 (2015) 12–21
Fig. 1. Structural 3D model of zEpor extracellular domain. (A), (B) Superimposition of zEpor (in blue) on hEPOR (in red) showing: (A) the residues involved in disulﬁde bond
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o  zEpor RefSeq: NP 001036799. (For interpretation of the references to color in thi
erved leucine residues (Leu265-266 and Leu254-255 in human
nd zebraﬁsh sequences, respectively), necessary for the correct
eceptor dimerization and the activation of the signaling cascade.
he cytoplasmic region of both proteins contained Box1 (aa 282-
90 in hEPOR, aa 271-279 in zEpor) and Box2 (aa 328-336 in
EPOR, aa 317-325 in zEpor), essential domains for the interac-
ion and activation of JAK2. Also the ITIM motif (aa 452-457),
ontaining two phospho-Tyr residues, was conserved. Three other
hospho-tyrosine (Tyr468, Tyr485 and Tyr489), important for
ownstream signaling, were conserved in hEPOR and zEpor pro-
eins.
To better evaluate the functional similarity between human
nd zebraﬁsh erythropoietin receptors andto assess if rhEPO could
ecognize and bind the zebraﬁsh erythropoietin receptor, a three-
imensional model of zEpor was created (Fig. S3). We  used I-Tasser
http://zhanglab.ccmb.med.umich.edu/I-TASSER/) and the struc-
ure of the extracellular portion of human EPOR (PDB: 1EER)
o generate the predicted structural model of zEpor extracellu-
ar domain by homology modeling [25]. Superimposition on the
uman protein structure revealed that the four cysteine putatively
nvolved in disulﬁde bonds in zEpor (Cys44, Cys54, Cys83 and
ys100) were placed near each other, in a conﬁguration compati-
le with the bond (Fig. 1A). Analysis of the 3 conserved residues
nvolved in EPO binding, namely Phe108, Ile164 and Tyr217,
howed that they were placed in a conﬁguration resembling those
f the human corresponding Phe117, Met174 and Phe229, respec-
ively (Fig. 1B). Moreover, the predicted contact surface of zEpor
as similar to that of hEPOR (Fig. 1C and D; Fig. S3) [26]. The molec-
lar docking of hEPO with the predicted structure of zEpor showed
lso an acceptable compatibility of contact surfaces (Sc score 0.507),
ompared to the score of the original human complex 1EER deter-
ined by crystallography (Sc score 0.71) [27,28].tween zEpor (in blue) and hEPO (in green) showing: (C) the contact between hEPO
nteraction between the two molecules (Sc score 0.507). Amino acid residues refers
e legend, the reader is referred to the web version of this article.)
3.2. Erythrocytes visualization and quantiﬁcation
To perform a functional analysis of rhEPO in vivo we con-
ducted several preliminary experiments in order to set the
optimal concentration to be used in zebraﬁsh embryos. We
diluted Eprex® in 0.05% phenol red solution (Sigma–Aldrich) to
a series of concentrations ranging from 2 to 48 IU/ml. The dif-
ferent Eprex® concentrations were injected into the common
cardinal vein of 48 hpf embryos and they were incubated at
28 ◦C for up to 12 h after injection. As negative control embryos
were injected with the 0.05% phenol red solution without drug.
Finally we performed an o-dianisidine staining to detect red blood
cells [13]. Time-course and concentration-curves demonstrated
a concentration-dependent increase in the erythrocytes number,
that reached its maximum 4 h after injection (data not shown).
Based on the results obtained in these preliminary experiments,
we used Eprex®, Binocrit® and Retacrit® at the concentration of
48 IU/ml.
To examine the in vivo effects of rhEPO administration on
zebraﬁsh erythropoiesis, the expression of 3 lineage-speciﬁc genes
was investigated by real time Q-RT-PCR after rhEPO treatment.
The analysis was  performed in triplicate and the experiment was
repeated twice, using different groups of embryos. Total RNA
was extracted from groups of 30 embryos injected with Eprex®,
Binocrit®, Retacrit® or negative controls and gene expression levels
were normalized using -actin as the housekeeping gene. The rel-
ative expression of gata1 was signiﬁcantly upregulated in embryos
treated with rhEPOs compared to the negative controls (2.4 ± 0.3
fold increase), as well as the relative expression of -eHB (1.87 ± 0.2
fold increase) and -eHb (1.57 ± 0.1 fold increase). No statistically
signiﬁcant differences in gene expression have been found between
Eprex® and its biosimilars (Fig. 2).
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Fig. 2. Relative gene expression levels of gata1, ˛-eHB and ˇ-eHb in embryos injected
with negative control (Neg ctrl), Eprex® , Binocrit® or Retacrit® . Q-RT-PCR was  per-
formed using total RNA extracted from groups of 30 embryos for each injected
compound. Data are expressed as fold change of target gene expression normal-
ized to the internal control gene (ˇ-actin). Data were analyzed according to the
comparative Ct method. Asterisks indicate statistically signiﬁcant fold changes of
the 3 target genes expression (p < 0.05). The experiment was repeated twice, using
different groups of embryos.
Fig. 3. Effects of Eprex® , Binocrit® and Retacrit® treatment on Stat5 phosphoryla-
tion. Western blot was  performed on total protein extracts obtained from groups
of  10 treated embryos. The anti-Phospho-Stat5 primary antibody revealed three
isoforms of phosphorylated Stat5, at around 90, 70 and 18 kDa respectively. The
a
w
e
R
t
o
I
v
F
d
(
R
f
c
p
a
s
a
(
i
region, but external stimuli can induce their migration to the site ofnti-actin primary antibody was  used as internal control. The western blot image
as  representative of 3 independent analysis.
To conﬁrm that rhEPO was functionally active on zebraﬁsh
mbryos, we investigated the effects of Eprex®, Binocrit® and
etacrit® injection on Jak/Stat pathway. The phosphorylation sta-
us of Stat5 protein was examined on total embryo protein extracts
btained from groups of 10 embryos for each injected compound.
ndeed, rhEPO binding to zEpor is expected to cause Jak2 acti-
ation, which leads to Stat5 phosphorylation [9]. As shown in
ig. 3, the rabbit anti-Phospho-Stat5 primary antibody was  able to
etect basal levels of 3 different isoforms of phosphorylated Stat5
Fig. 3, lane 1) [40]. After treatment with Eprex®, Binocrit® and
etacrit® the phosphorylation of Stat5, especially the shortest iso-
orm, was clearly upregulated respect to the untreated negative
ontrols (Fig. 3). Of note, to the best of our knowledge, only few
apers studying phospho-Stat5 on total embryo protein extracts
re available in literature. We  will further investigate why  the
hortest isoform of Stat5 resulted the most phosphorylated one
fter rhEPO treatment.The three rhEPOs were then injected in groups of 25 tg
kdrl:EGFP; gata1:ds-red) casper embryos, for subsequent live
maging acquisition. Double-channel ﬂuorescence images (Fig. 4A)l Research 102 (2015) 12–21 17
revealed that blood vessels (expressing EGFP) were pervious and
red blood cells (expressing ds-red) were able to easily circu-
late in the whole embryo. Images acquired in single-red channel
(Fig. 4B) highlighted an increase of ﬂuorescence intensity in
embryos injected with Eprex®, Binocrit® and Retacrit® compared
to the negative controls. This effect was  caused by the higher
number of circulating erythrocytes in embryos treated with rhE-
POs. It could be visualized both in the principal vessels (i.e. dorsal
aorta and posterior cardinal vein) and in the smallest blood ves-
sels (i.e. intersegmental vessels and caudal venous plexus) [30].
Quantiﬁcation of the red and green ﬂuorescence signal, performed
using ImageJ analysis software, is reported in Fig. 4C and D as
a mean of 3 independent experiments. The red signal intensity,
proportional to the circulating erythrocytes, was 2.13 ± 0.09 fold
higher in embryos treated with rhEPOs compared to the negative
controls. No statistically signiﬁcant differences were highlighted
between the three biosimilars (Fig. 4C). On the contrary, the green
signal intensity, produced by the endothelial cells of the blood ves-
sels, remained constant in all the analyzed embryos (Fig. 4D).
Groups of 25 wild type embryos were ﬁxed in 4% paraformalde-
hyde after injection with negative control or Eprex®, Binocrit®
and Retacrit®, each group was  incubated in o-dianisidine stain-
ing buffer and then photographed (Fig. 5A). Hemoglobin catalyzes
the oxidation of o-dianisidine, producing a dark red-brown stain in
cells containing hemoglobin [13]. Erythrocytes were quantiﬁed in
the trunk and in the tail of each embryo by using ImageJ analysis
software. Fig. 5B reports the results of three independent experi-
ments: the percentage of o-dianisidine positive area is proportional
to the amount of red blood cells measured in the region of interest.
Embryos treated with rhEPOs showed a 1.67 ± 0.06 fold increase
of erythrocytes content when compared to the negative controls.
Interestingly, no differences have been found between Eprex® and
its biosimilars also in the o-dianisidine staining assay.
These data were conﬁrmed with a quantitative hemoglobin
assay on total embryo extract by using a modiﬁed cyanomethe-
moglobin method [33]. According to the manufacturer, Drabkin’s
solution (Sigma–Aldrich) reacts with hemoglobin causing its oxi-
dation to methemoglobin. In the presence of potassium cyanide,
methemoglobin is converted to cyanomethemoglobin, which max-
imum absorbance can be measured at 540 nm. Groups of 20 wild
type embryos injected with negative control solution or Eprex®,
Binocrit® and Retacrit® were anesthetized in tricaine and used for
the Drabkin assay. Fig. 5C shows the cyanomethemoglobin opti-
cal density (O.D.) at 540 nm of each group of treated embryos, as a
mean of three independent experiments. The hemoglobin content
was signiﬁcantly increased (1.53 ± 0.05 fold) in embryos treated
with rhEPO when compared with the negative control.
The results showed that Eprex®, Binocrit® and Retacrit® were
able to interact with zebraﬁsh epo-receptor, leading to an increase
of hemoglobin content, proportional to the number of circulating
erythrocytes. When compared among them Eprex®, Binocrit® and
Retacrit® did not show any statistically signiﬁcant differences.
3.3. Macrophages and granulocytes quantiﬁcation
We then investigated whether Eprex® and its biosimilars
Binocrit® and Retacrit® were able to activate primitive mono-
cytes/macrophages and granulocytes neutrophils to induce an
inﬂammatory state. The three rhEPOs samples, negative and pos-
itive (E. coli JM109 bacteria) controls were injected into the otic
capsule of groups of 40 healthy zebraﬁsh embryos at 72 hpf. It is
well known that leukocytes are normally absent in that anatomicalinfection/inﬂammation [31]. Moreover, it has been demonstrated
that at this stage monocytes/macrophages are present in higher
number and have more phagocytic activity than granulocytes neu-
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Fig. 4. Negative control (Neg ctrl), Eprex® , Binocrit® or Retacrit® injected in 48 hpf tg (kdrl:EGFP; gata1:ds-red) casper embryos and photographed after 4 h. (A) Double channel
ﬂuorescence: in green blood vessels, expressing kdrl:EGFP and in red circulating erythrocytes, expressing gata1:ds-red. Lateral views, anterior to the left, 11.5X magniﬁcation;
(B)  single red-channel ﬂuorescence shows circulating erythrocytes, expressing gata1:ds-red. Lateral views, anterior to the left, 4X magniﬁcation. Quantiﬁcation of (C) red
ﬂuorescence signal and (D) green ﬂuorescence signal, measured with ImageJ 1.45 s image analysis software on a mean of 25 embryos for each experimental point. Asterisk
indicates statistically signiﬁcant increase of the positive area (p < 0.05), data are the mean ± S.D. of 3 independent experiments. (For interpretation of the references to color
in  this ﬁgure legend, the reader is referred to the web  version of this article.)
Fig. 5. O-dianisidine staining and Drabkin assay quantiﬁcation of 48 hpf wild type AB embryos injected with negative control (Neg ctrl), Eprex® , Binocrit® or Retacrit® . (A)
Representative images of embryos stained with o-dianisidine 4 h after treatment. Lateral views, anterior to the left, 4X magniﬁcation; (B) quantiﬁcation of o-dianisidine
positive area in the region of trunk and tail, measured with ImageJ 1.45 s image analysis software on a mean of 25 embryos for each experimental point. Asterisk indicates
statistically signiﬁcant increase of the positive area (p < 0.05), data are the mean ± S.D. of 3 measurements; (C) cyanomethemoglobin absorbance measured at 540 nm,
proportional to the amount of red blood cells in groups of 20 embryos. Asterisk indicates statistically signiﬁcant increase of absorbance (p < 0.05), data are the mean ± S.D. of
3  measurements.
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epresentative images of 72 hpf embryos injected into the otic capsule with Eprex® , 
ateral views, anterior to the left, 11.5X magniﬁcation; (B) quantiﬁcation of pu1, lp
ean  of 40 embryos for each experimental point. Asterisk indicates statistically sign
rophils [31]. Primitive leukocytes were detected by WISH, using
u1, lplastin and mpx  as molecular probes. The transcription fac-
or pu1 is essential for early hematopoiesis, in particular for the
yeloid cell development, including both macrophages and gran-
locytes precursor. The actin-binding protein encoded by lplastin
s predominately expressed in monocytes/macrophages, while the
nzyme myeloperoxidase, encoded by mpx, is tipically located in
eutrophils granules [7,35].
Fig. 6 reports leukocytes response to the injection into the otic
apsule of groups of 40 embryos, as the mean of three indepen-
ent experiments. As expected, the amount of macrophages was
bout twice the number of neutrophils in the otic capsule and in the
urrounding area of all the analyzed embryos. Both macrophages
nd neutrophils were strongly attracted to the injection site by the
resence of the positive control of E. Coli bacteria, while the neg-
tive control had a very mild effect on leukocytes, similar to that
f Eprex® and its biosimilars Binocrit® and Retacrit® (Fig. 6A). The
eukocytes signal intensity in positive controls was  2.25 fold higher
han negative controls for pu1 probe, 2.35 fold higher for lplastincursors, monocytes/macrophages and granulocytes neutrophils, respectively. (A)
rit® or Retacrit® and positive or negative control (Pos ctrl and Neg ctrl, respectively).
 and mpx positive area, measured with ImageJ 1.45 s image analysis software on a
 increase of the positive area (p < 0.05), data are the mean ± S.D. of 3 measurements.
probe and 4.49 fold higher for mpx probe (Fig. 6B). On the con-
trary, the signal quantiﬁcation for all the three probes in embryos
treated with rhEPOs was comparable to that of the negative
controls (1.01 ± 0.09 fold increase, Fig. 6B). The results showed that
Eprex®, Binocrit® and Retacrit® were able to act on EPO-receptor
without causing any acute pro-inﬂammatory effects on the
zebraﬁsh embryos.
4. Conclusions
Due to its valuable characteristics, in the last decade the
zebraﬁsh embryo has been widely used as a vertebrate model for
high throughput screening of chemicals. However, more recently
it has been increasingly exploited to test not only chemically
synthesized drugs, but also more complex molecules (i.e.,  bio-
pharmaceuticals) [1–3]. In this paper, we used the zebraﬁsh
embryo to perform in vivo pharmacological assays. We  performed
a functional analysis of human recombinant erythropoietin alpha
Eprex® and its biosimilars Binocrit® and Retacrit®. The recombi-
2 logica
n
a
l
i
n
t
c
e
w
s
T
a
i
t
0
r
a
i
g
i
S
e
b
e
t
c
a
w
o
p
b
m
b
c
t
b
c
t
s
a
w
C
A
(
A
i
0
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[0 M. Guarienti et al. / Pharmaco
ant molecules, industrially produced in CHO cells, have the same
mino acid sequence of endogenous hEPO but differ in the glycosy-
ation pattern. This may  inﬂuence efﬁcacy and safety, particularly
mmunogenicity, of the ﬁnal product [38,39].
Data obtained by computational analysis and 3D modeling tech-
iques strongly suggested that rhEPO could recognize and bind
he zebraﬁsh erythropoietin receptor. The 3D model of zEpor was
reated by homology modeling starting from the structure of the
xtracellular portion of hEPOR. It conﬁrmed the results obtained
ith the ClustalW multiple sequence alignment, in particular the
tructural conservation of the most important functional residues.
he analysis of surfaces putatively involved in EPO binding revealed
 high degree of similarity between zEpor and hEPOR structure,
ndeed the molecular docking of hEPO with the predicted struc-
ure of zEpor showed a compatibility of contact surfaces (Sc score
.507). These data supported the hypothesis that hEPO could be
ecognized and bound by the zEpor.
Then it was demonstrated that Eprex® and its biosimilars were
ble to produce a signiﬁcant increase of the number of circulat-
ng erythrocytes in treated embryos. The relative expression of
ata1, -eHB and -eHb transcripts was signiﬁcantly upregulated
n embryos treated with rhEPOs, as well as the phosphorylation of
tat5 protein. Live imaging in tg (kdrl:EGFP; gata1:ds-red) casper
mbryos revealed that both the principal vessels and the smallest
lood vessels were pervious and the concentration of circulating
rythrocytes was higher in embryos treated with rhEPO respect
o the negative controls. Also o-dianisidine positive area quantiﬁ-
ation and cyanomethemoglobin content quantiﬁcation revealed
 signiﬁcant increase of erythrocytes amount in embryos treated
ith rhEPOs when compared with the negative controls.
Finally, this experimental animal model conﬁrmed the lack
f immunogenicity, required for the regulatory approval of bio-
harmaceutical drugs. Indeed embryos injected with Eprex® or its
iosimilars showed an almost null effect on activation of primitive
onocytes/macrophages and granulocytes neutrophils, compara-
le to that of negative controls.
In conclusion, our data demonstrated that zebraﬁsh embryo
ould represent an new, reproducible and robust experimental ver-
ebrate animal model to study the efﬁcacy and the safety of complex
iotherapeutics and biosimilars, such as recombinant human gly-
oproteins. Indeed, using the zebraﬁsh embryo, we  were able to
est in vivo effects of rhEPO, in terms of both biological activity and
afety. Zebraﬁsh embryo demonstrated to be a valuable tool, that
llows to perform fast and reproducible pharmacological assays
ith excellent results.
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